Nick Paul TaylorGene silencing and gene editingEngineered Cas clears barrier to antiviral CRISPR therapiesResearchers have engineered a Cas enzyme to enhance activity against RNA viruses, resulting in a system that completely blocked the replication of various SARS-CoV-2 strains.April 19, 2024Artificial IntelligenceAI-powered endoscope doubles detection of high-risk esophageal lesionsDeep learning has doubled the detection of high-risk lesions during routine endoscopies in a clinical trial of more than 3,000 patients in China.April 17, 2024Prostate CancerLipid enzyme blocker renders prostate cancer cells vulnerable to PARP inhibitors in studyBlocking lipid synthesis enhanced the effect of PARP inhibitors on prostate cancer in a preclinical study, pointing to a potential way to make the treatments effective in more patients.April 15, 2024Bladder CancerUrine test halves use of invasive procedure to monitor bladder cancerA urine test can cut the number of cystoscopies necessary to follow up high-risk bladder cancer patients without increasing the risk of recurrence, a study has found.April 11, 2024TuberculosisResearchers tweak TB treatment assay to support global useResearchers have developed a tuberculosis (TB) treatment assay that could be a faster, simpler method for monitoring patients.April 10, 2024Artificial IntelligenceAI foundation models set new benchmarks in computational pathologyMass General Brigham researchers have published a pair of papers on artificial intelligence (AI) systems that could improve tasks that include the analysis of pathology images and identification of rare diseases.March 20, 2024InfectiousNew class of broad-spectrum antivirals could be first line of pandemic defense: StudyTargeting a cellular pathway has inhibited SARS-CoV-2 and other RNA viruses in preclinical tests, pointing to a potential new class of first-line antivirals with broad effectiveness against emerging pathogens.March 5, 2024Gene silencing and gene editingReversible, multiplex CRISPR system enhances efficacy of CAR-T cell therapyA CRISPR system that uses Cas13d to make reversible changes to the expression of multiple genes could overcome limitations that are holding back CAR-T cell therapies, a paper published in Cell suggests.February 28, 2024Lupus‘Remarkable’ results in lupus patients spark speculation CAR-T may cure autoimmunityThe generation of “remarkable” results in lupus patients has sparked speculation about the potential for chimeric antigen receptor T-cell (CAR-T cell) therapy to cure autoimmune diseases.February 23, 2024MonkeypoxCRISPR and nanopore technology enable sensitive and specific mpox detectionA test that combines CRISPR gene editing and nanopore sensing technology could accelerate the detection of mpox and other pathogens, according to a paper published in Biosensors and Bioelectronics.February 16, 2024Page 1 of 17Next PageTop StoriesLawsuitU.K. Patents Court rules Bio-Techne patents invalid in infringement lawsuitThe Patents Court of the High Court of England and Wales has ruled that two patents owned by Bio-Techne are invalid, rejecting a patent infringement lawsuit filed by Bio-Techne/ACD in the U.K. against Molecular Instruments.Point-of-Care TestingScout secures CARB-X grant to advance diagnostic test developmentSequencingMission Bio launches new features for Tapestri platformAlzheimer'sQuest adds new biomarker test to Alzheimer's portfolioSponsor ContentVisit our Molecular Diagnostics Community
